Jae Heon Kim1,2, Shufeng Li3, Yash Khandwala1,4, Kyung Jin Chung1, Hyung Keun Park1, Benjamin I Chung1. 1. Department of Urology, Stanford University Medical Center, Stanford, California. 2. Department of Urology, Soonchunhyang University Hospital, Soonchuhyang University Medical College, Seoul, Korea. 3. Department of Urology and Dermatology, Stanford University Medical Center, Stanford, California. 4. San Diego School of Medicine, University of California, San Diego.
Abstract
Importance: Although the intent of nephron-sparing surgery is to eradicate malignant tumors found on preoperative imaging, benign masses often cannot be differentiated from malignant tumors. However, in the past there have been discrepancies in the reported percentages of benign masses removed by partial nephrectomy (PNx). Objective: To investigate the annual trend of prevalence of benign pathologic findings after PNx and to investigate what potential factors are associated with this prevalence. Design, Setting, and Participants: A total of 18 060 patients who underwent PNx between 2007 and 2014 were selected from Truven Health MarketScan Research Databases. We selected those patients who underwent PNx as an inpatient from 2007 and set the surgery date as the index date. Overall, a total of 21 445 patients with International Classification of Diseases, Ninth Revision, Clinical Modification code of 55.4 were identified from 2007 to 2015. Main Outcomes and Measures: The annual trend of benign pathologic findings was described as an actual number and as a proportion. Univariate and multiple analyses were performed to investigate factors predictive of a benign final pathologic diagnosis, including type of preoperative imaging modality or performance of a renal mass biopsy. Results: Among the 18 060 patients, mean (SD) age was 57 (12) years, and there were 10637 (58.9%) men and 7423 (41.1%) women. The overall prevalence of benign pathologic findings was 30.9% and the annual trends demonstrated a prevalence of over 30% for nearly every year of the study period. On univariate analysis, the performance of magnetic resonance imaging (MRI) and renal mass biopsy was associated with benign pathologic findings (P = .02 and P < .001, respectively). On multivariable analysis, female sex (odds ratio [OR], 0.62; 95% CI, 0.58-0.66; P < .001), older age (>65 years) (OR, 0.99; 95% CI, 0.99-0.99; P < .001), and computed tomography (CT) only preoperative imaging (OR, 1.16; 95% CI, 1.05-1.28; P = .004) were associated with benign pathologic findings after PNx. Conclusions and Relevance: We found that the overall prevalence of benign pathologic findings after PNx was higher than the literature suggests, with consistent year-over-year rates exceeding 30%. Female sex, older age (>65 years), and CT only preoperative imaging were predictive of a benign tumor. Further elucidation concerning covariates associated with a benign diagnosis should be the focus of future investigations to identify a cohort of patients who could potentially avoid unnecessary surgical intervention.
Importance: Although the intent of nephron-sparing surgery is to eradicate malignant tumors found on preoperative imaging, benign masses often cannot be differentiated from malignant tumors. However, in the past there have been discrepancies in the reported percentages of benign masses removed by partial nephrectomy (PNx). Objective: To investigate the annual trend of prevalence of benign pathologic findings after PNx and to investigate what potential factors are associated with this prevalence. Design, Setting, and Participants: A total of 18 060 patients who underwent PNx between 2007 and 2014 were selected from Truven Health MarketScan Research Databases. We selected those patients who underwent PNx as an inpatient from 2007 and set the surgery date as the index date. Overall, a total of 21 445 patients with International Classification of Diseases, Ninth Revision, Clinical Modification code of 55.4 were identified from 2007 to 2015. Main Outcomes and Measures: The annual trend of benign pathologic findings was described as an actual number and as a proportion. Univariate and multiple analyses were performed to investigate factors predictive of a benign final pathologic diagnosis, including type of preoperative imaging modality or performance of a renal mass biopsy. Results: Among the 18 060 patients, mean (SD) age was 57 (12) years, and there were 10637 (58.9%) men and 7423 (41.1%) women. The overall prevalence of benign pathologic findings was 30.9% and the annual trends demonstrated a prevalence of over 30% for nearly every year of the study period. On univariate analysis, the performance of magnetic resonance imaging (MRI) and renal mass biopsy was associated with benign pathologic findings (P = .02 and P < .001, respectively). On multivariable analysis, female sex (odds ratio [OR], 0.62; 95% CI, 0.58-0.66; P < .001), older age (>65 years) (OR, 0.99; 95% CI, 0.99-0.99; P < .001), and computed tomography (CT) only preoperative imaging (OR, 1.16; 95% CI, 1.05-1.28; P = .004) were associated with benign pathologic findings after PNx. Conclusions and Relevance: We found that the overall prevalence of benign pathologic findings after PNx was higher than the literature suggests, with consistent year-over-year rates exceeding 30%. Female sex, older age (>65 years), and CT only preoperative imaging were predictive of a benign tumor. Further elucidation concerning covariates associated with a benign diagnosis should be the focus of future investigations to identify a cohort of patients who could potentially avoid unnecessary surgical intervention.
Authors: Jason Hafron; James D Fogarty; David M Hoenig; Maomi Li; Robert Berkenblit; Reza Ghavamian Journal: Urology Date: 2005-12 Impact factor: 2.649
Authors: Alexander Kutikov; Lindsay K Fossett; Parvati Ramchandani; John E Tomaszewski; Evan S Siegelman; Marc P Banner; Keith N Van Arsdalen; Alan J Wein; S Bruce Malkowicz Journal: Urology Date: 2006-10 Impact factor: 2.649
Authors: Martin Marszalek; Anton Ponholzer; Clemens Brössner; Johann Wachter; Ulrich Maier; Stephan Madersbacher Journal: Urology Date: 2004-07 Impact factor: 2.649
Authors: M Raquel Oliva; Jonathan N Glickman; Kelly H Zou; Sze Y Teo; Koenraad J Mortelé; Manoel S Rocha; Stuart G Silverman Journal: AJR Am J Roentgenol Date: 2009-06 Impact factor: 3.959
Authors: Inderbir S Gill; Surena F Matin; Mihir M Desai; Jihad H Kaouk; Andrew Steinberg; Ed Mascha; Julie Thornton; Mahmoud H Sherief; Brenda Strzempkowski; Andrew C Novick Journal: J Urol Date: 2003-07 Impact factor: 7.450
Authors: Andrew W Silagy; Alejandro Sanchez; Brandon J Manley; Karim Bensalah; Axel Bex; Jose A Karam; Börje Ljungberg; Brian Shuch; A Ari Hakimi Journal: Eur Urol Focus Date: 2019-04-28
Authors: Michael Baboudjian; Daniel Moser; Takafumi Yanagisawa; Bastien Gondran-Tellier; Eva M Compérat; Damien Ambrosetti; Laurent Daniel; Cyrille Bastide; Shahrokh F Shariat; Eric Lechevallier; Pietro Diana; Alberto Breda; Benjamin Pradere; Romain Boissier Journal: Eur Urol Open Sci Date: 2022-05-19
Authors: Christiaan V Widdershoven; Brigitte M Aarts; Axel Bex; Brunolf W Lagerveld; Patricia J Zondervan; Michaël M E L Henderickx; Elisabeth G Klompenhouwer; Otto M van Delden; Warner Prevoo; Alexander D Montauban van Swijndregt; Reindert J A van Moorselaar Journal: Abdom Radiol (NY) Date: 2020-06-20
Authors: Flora E Rodger; Keiran Brown; Steve Leung; Jack Coode-Bate; James Armitage; Anne Warren; Jane Hendry; Grant D Stewart; Alex Laird; Grenville M Oades Journal: BJUI Compass Date: 2022-03-03